In a significant development within the pharmaceutical sector, Sun Pharmaceutical Industries has reached a definitive agreement to acquire Organon & Co. through an all-cash transaction valued at $11.75 billion. This strategic maneuver is poised to reshape the landscape of established brands and branded generics, catapulting Sun Pharma into a leading position among global drug manufacturers.
The terms of the acquisition stipulate that Organon's shareholders will receive $14 per share in cash, representing a substantial 103% premium over its closing share price on April 9th. Both companies' Boards of Directors have given their approval for the transaction, which is anticipated to be finalized in early 2027, subject to the necessary regulatory green lights. This deal underscores Sun Pharma's ambition to significantly broaden its market reach and product portfolio.
Organon, which originated as a spin-off from Merck & Co. Inc. in 2021, boasts a diverse portfolio of over 70 products spanning women's health and general medicine, including biosimilars. Its global footprint extends across more than 140 countries, making it an attractive target for Sun Pharma's expansion objectives. The integration of Organon's offerings and its established stakeholder relationships is expected to synergize with Sun Pharma's existing strengths, fostering long-term value creation and market dominance.
Upon the successful completion of this acquisition, Sun Pharma is set to emerge as a formidable force in the pharmaceutical industry. The combined entity is projected to generate approximately $12.4 billion in annual revenue, positioning it among the top 25 global drugmakers. This consolidation will also lead to an innovation-driven enterprise, with about 27% of its revenue derived from groundbreaking medicines, and an expanded presence across 150 countries, including 18 key markets each contributing over $100 million in revenue.
Furthermore, the combined company is expected to become a top-three global player in women's health and secure the seventh position worldwide in biosimilars. The financial outlook for the new entity is robust, with expectations of nearly doubling its EBITDA and cash flow, which will facilitate the reduction of net debt post-transaction to a healthy 2.3x multiple of EBITDA. Following the announcement, Organon's shares saw a notable increase of 16.8% in Robinhood's 24-hour market, building on a roughly 31% surge experienced on the preceding Friday.
This acquisition marks a pivotal moment for both Organon and Sun Pharma, promising a future of enhanced market leadership and innovation in the pharmaceutical sector. The integration of Organon's diverse product range and global presence with Sun Pharma's strategic vision is anticipated to create a powerhouse capable of delivering substantial value to shareholders and patients alike.